These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23941629)

  • 1. Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound.
    Menning MM; Dalziel SM
    Mol Pharm; 2013 Nov; 10(11):4005-15. PubMed ID: 23941629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug.
    Kranz H; Le Brun V; Wagner T
    Int J Pharm; 2005 Aug; 299(1-2):84-91. PubMed ID: 15970409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
    Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
    Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
    Sawicki E; Schellens JH; Beijnen JH; Nuijen B
    Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
    Taupitz T; Dressman JB; Klein S
    Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
    Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G
    Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
    Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
    Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
    Cao QR; Choi YW; Cui JH; Lee BJ
    J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study on moisture isotherms of formulations: the use of polynomial equations to predict the moisture isotherms of tablet products.
    Li Y; Sanzgiri YD; Chen Y
    AAPS PharmSciTech; 2003 Dec; 4(4):E59. PubMed ID: 15198554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study.
    Siepe S; Herrmann W; Borchert HH; Lueckel B; Kramer A; Ries A; Gurny R
    J Control Release; 2006 May; 112(1):72-8. PubMed ID: 16476499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naftopidil-fumaric acid interaction in a solid dispersion system: Improving the dissolution rate and oral absorption of naftopidil in rats.
    Choi JS; Byeon JC; Park JS
    Mater Sci Eng C Mater Biol Appl; 2019 Feb; 95():264-274. PubMed ID: 30573249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and optimizing the dual excipient functionality of sodium lauryl sulfate in tablet formulation of poorly water soluble drug: wetting and lubrication.
    Aljaberi A; Chatterji A; Dong Z; Shah NH; Malick W; Singhal D; Sandhu HK
    Pharm Dev Technol; 2013; 18(2):490-503. PubMed ID: 23009028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form.
    Zannou EA; Ji Q; Joshi YM; Serajuddin AT
    Int J Pharm; 2007 Jun; 337(1-2):210-8. PubMed ID: 17296277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability and repeatability of a continuous twin screw granulation and drying system.
    Vercruysse J; Delaet U; Van Assche I; Cappuyns P; Arata F; Caporicci G; De Beer T; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1031-8. PubMed ID: 23702273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro monitoring of dissolution of an immediate release tablet by focused beam reflectance measurement.
    Coutant CA; Skibic MJ; Doddridge GD; Kemp CA; Sperry DC
    Mol Pharm; 2010 Oct; 7(5):1508-15. PubMed ID: 20715796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and evaluation of Cetirizine dihydrochloride orodispersible tablet.
    Subramanian S; Sankar V; Manakadan AA; Ismail S; Andhuvan G
    Pak J Pharm Sci; 2010 Apr; 23(2):232-5. PubMed ID: 20363705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical evaluation and dynamic vapor sorption studies of fast dissolving intraoral films of Loratadine.
    Arya A; Sharma V; Pathak K
    Pharm Dev Technol; 2013; 18(6):1329-38. PubMed ID: 22663089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug.
    Kranz H; Guthmann C; Wagner T; Lipp R; Reinhard J
    Eur J Pharm Sci; 2005 Sep; 26(1):47-53. PubMed ID: 15953712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.